ArticleVaccine2007
Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope.
Article in Vaccine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- A systematic review of SARS-CoV-2 vaccine candidates.Signal transduction and targeted therapy · 2020Pooled it
- Drug targets for corona virus: A systematic review.Indian journal of pharmacologyPooled it
- Review
- Highly Networked SARS-CoV-2 Peptides Elicit T Cell Responses with Enhanced Specificity.ImmunoHorizons · 2023Article
- Review on Approved and Inprogress COVID-19 Vaccines.Iranian journal of pharmaceutical research : IJPR · 2022Review
- Intrinsic Folding Properties of the HLA-B27 Heavy Chain Revealed by Single Chain Trimer Versions of Peptide-Loaded Class I Major Histocompatibility Complex Molecules.Frontiers in immunology · 2022Article
- Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics.Cell reports · 2021Article
- Landscape and selection of vaccine epitopes in SARS-CoV-2.Genome medicine · 2021Article
- Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.Human vaccines & immunotherapeutics · 2021Review
- The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies.International immunopharmacology · 2021Review
- The presentation of SARS-CoV-2 peptides by the common HLA-AiScience · 2021Article
- DNA vaccines against COVID-19: Perspectives and challenges.Life sciences · 2021Review
- SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets.Biochimica et biophysica acta. Molecular basis of disease · 2020Review
- Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19).Journal of molecular medicine (Berlin, Germany) · 2020Review
- Comprehensive Review on Current Interventions, Diagnostics, and Nanotechnology Perspectives against SARS-CoV-2.Bioconjugate chemistry · 2020Review
- Vaccination strategies to combat novel corona virus SARS-CoV-2.Life sciences · 2020Review
- Identification and Analysis of Unstructured, Linear B-Cell Epitopes in SARS-CoV-2 Virion Proteins for Vaccine Development.Vaccines · 2020Article
- Article
- Landscape and Selection of Vaccine Epitopes in SARS-CoV-2.bioRxiv : the preprint server for biology · 2020Article
- A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2.Cell host & microbe · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The severe acute respiratory syndrome coronavirus nucleocapsid protein (SARS-CoV N) is one of the major targets for SARS vaccine due to its high potency in triggering immune responses. In this study, we have identified a novel HLA-A*0201 restricted epitope, N220 (LALLLLDRL), of the SARS-CoV N-protein through bioinformatics analysis. The N-protein peptide N220 shows a high binding affinity towards human MHC class I in T2-cells, and is capable of activating cytotoxic T-cells in human peripheral blood mononuclear cells (PBMCs). The application of using the N220 peptide sequence with a single-chain-trimer (SCT) approach to produce a potential DNA vaccine candidate was investigated in HLA-A2.1K(b) transgenic mice. Cytotoxicity assay clearly showed that the T-cells obtained from the vaccinated animals were able to kill the N-protein expressing cells with a cytotoxicity level of 86% in an effector cells/target cells ratio of 81:1 one week after the last vaccination, which is significantly higher than other N-protein peptides previously described. The novel immunogenic N-protein peptide revealed in the present study provides valuable information for therapeutic SARS vaccine design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.